Marimed (MRMD) Cost of Revenue (2011 - 2026)

Marimed (MRMD) has 16 years of Cost of Revenue data on file, last reported at $24.2 million in Q1 2026.

• On a quarterly basis, Cost of Revenue rose 6.08% year-over-year to $24.2 million in Q1 2026; TTM through Mar 2026 was $103.3 million, a 7.13% increase from a year earlier, with the FY2025 full-year figure at $101.9 million, up 7.2% from the prior year.
• Cost of Revenue for Q1 2026 stood at $24.2 million, down from $31.1 million in the prior quarter.
• Over the last five years, Cost of Revenue for MRMD reached as high as $31.1 million in Q4 2025 and fell as low as $14.3 million in Q1 2022.
• Historically, Cost of Revenue has averaged $22.0 million across 5 years, with a median of $22.0 million in 2023.
• Across the five-year window, Cost of Revenue soared 36.6% in 2022 and rose 0.21% in 2025, its largest moves.
• Year by year, Cost of Revenue stood at $20.0 million in 2022, then gained by 7.81% to $21.6 million in 2023, then rose by 21.83% to $26.3 million in 2024, then grew by 18.46% to $31.1 million in 2025, then retreated by 22.29% to $24.2 million in 2026.
• Per Business Quant data, the three most recent Cost of Revenue figures were $24.2 million in Q1 2026, $31.1 million in Q4 2025, and $24.4 million in Q3 2025.